Arialys Therapeutics
PrivateLast Round
Seed
Sep 12, 2023
Total Funding Raised
$58M
Company Overview
Arialys Therapeutics operates in Healthcare & Life Sciences and is based in La Jolla, California. Its latest recorded funding round was a Seed round in September 2023.
Arialys Therapeutics is a biotechnology company that develops precision medicines to treat autoimmune neuropsychiatric diseases by blocking pathogenic autoantibodies in the brain.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Arialys Therapeutics Comparables
Compare Arialys Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Santa Ana Bio | 63% | |
| STALICLA | 62% | |
| Roche Holding | 61% |
For institutional investors. Book with your work email.
Arialys Therapeutics Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Arialys Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| MPM BioImpact | Seed |
| Alexandria Venture Investments | Seed |
| Catalys Pacific | Seed |
| Avalon BioVentures | Seed |
| Johnson & Johnson Innovation – JJDC | Seed |
| Johnson & Johnson Innovation - JJDC, Inc. | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 12, 2023
$58M round led by Johnson & Johnson Innovation and Avalon BioVentures.
For institutional investors. Book with your work email.
Arialys Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Arialys Therapeutics's valuation, stock price, and market status.
Is Arialys Therapeutics a public or private company?
Arialys Therapeutics is a private company.
What is the current stock price of Arialys Therapeutics?
Arialys Therapeutics is a private company, so its shares have no public market price. Caplight tracks Arialys Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Arialys Therapeutics worth (valuation)?
Valuation information for Arialys Therapeutics is not publicly available.
Can I buy Arialys Therapeutics stock?
Arialys Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Arialys Therapeutics's last funding round?
Arialys Therapeutics's most recent funding round was Seed on September 12, 2023.
Who are the main investors in Arialys Therapeutics?
Key investors in Arialys Therapeutics include Avalon BioVentures, Johnson & Johnson Innovation - JJDC, Inc..
Will Arialys Therapeutics IPO soon?
No public IPO plans have been announced for Arialys Therapeutics.
How can I track Arialys Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Arialys Therapeutics's shares on secondary markets.